Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study

(1) Background: Efavirenz plasma concentration displays wide between-patient variability partly due to pharmacogenetic variation and autoinduction. Pediatric data on efavirenz pharmacokinetics and the relevance of pharmacogenetic variation are scarce, particularly from sub-Saharan Africa, where >...

Full description

Bibliographic Details
Main Authors:	Adugna Chala, Birkneh Tilahun Tadesse, Tolossa Eticha Chaka, Jackson Mukonzo, Eliford Ngaimisi Kitabi, Sintayehu Tadesse, Anton Pohanka, Eyasu Makonnen, Eleni Aklillu
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Series:	Journal of Personalized Medicine
Subjects:	efavirenz CYP2B6 autoinduction pharmacogenetics children
Online Access:	https://www.mdpi.com/2075-4426/11/12/1303

Similar Items

Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia
by: Adugna Chala, et al.
Published: (2023-06-01)

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania
by: Selemani Saidi Sungi, et al.
Published: (2018-10-01)

<i>CYP3A</i> and <i>CYP2B6</i> Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study
by: Wondmagegn Tamiru Tadesse, et al.
Published: (2022-06-01)

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis
by: Nathan W. Cummins, et al.
Published: (2015-07-01)

Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations
by: Sabina Mugusi, et al.
Published: (2020-02-01)

Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study
by: Birkneh Tilahun Tadesse, et al.
Published: (2019-09-01)

An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3'-UTR single nucleotide polymorphisms among Black South African HIV/AIDS patients
by: Marelize eSwart, et al.
Published: (2016-01-01)

PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients
by: Swart Marelize, et al.
Published: (2012-11-01)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz
by: Manoranjenni Chetty, et al.
Published: (2018-03-01)

7,8-Dihydroxy Efavirenz Is Not as Effective in CYP46A1 Activation In Vivo as Efavirenz or Its 8,14-Dihydroxy Metabolite
by: Natalia Mast, et al.
Published: (2024-02-01)

Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients
by: Jemal Hussien Ahmed, et al.
Published: (2020-04-01)

Efavirenz and neuropsychiatric effects
by: Mukesh Dheda
Published: (2017-04-01)

Pharmacogenetic Associations Between Atazanavir/UGT1A1*28 and Efavirenz/rs3745274 (CYP2B6) Account for Specific Adverse Reactions in Chilean Patients Undergoing Antiretroviral Therapy
by: Daniela Poblete, et al.
Published: (2021-05-01)

CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil
by: TALISE E. MÜLLER, et al.

Influence of milling process on efavirenz solubility
by: Erizal Zaini, et al.
Published: (2017-01-01)

A Case Series of Efavirenz Induced Gynaecomastia
by: Charu Jain , Neha Sharma , Uma Advani , Lokendra Sharma , Munesh Kumar , Monica Jain
Published: (2023-08-01)

ABCB1 4036A>G and 1236C>T polymorphisms affect plasma efavirenz levels in South African HIV/AIDS patients
by: Marelize eSwart, et al.
Published: (2012-11-01)

Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia
by: Birkneh Tilahun Tadesse, et al.
Published: (2019-09-01)

Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes.
by: Santosh ePhilips, et al.
Published: (2012-03-01)

Safety, strength and simplicity of efavirenz in pregnancy
by: Prinitha Pillay, et al.
Published: (2012-03-01)

The Cyp2b6 Gene Polymorphism and Phenotypic Correlation of Efavirenz-Based Combination Therapy Among the Niger Delta Ethnic Population: Implications in Modern Pharmacogenomics
by: Bunu JS, et al.
Published: (2022-01-01)

Como pesquisar o perfil patentário de um fármaco: o caso Efavirenz How to determine the patent profile of a drug: a case study of Efavirenz
by: Jaqueline Mendes Soares, et al.
Published: (2010-01-01)

Low-Dose Anti-HIV Drug Efavirenz Mitigates Retinal Vascular Lesions in a Mouse Model of Alzheimer’s Disease
by: Nicole El-Darzi, et al.
Published: (2022-06-01)

Efavirenz: History, Development and Future
by: Bárbara Costa, et al.
Published: (2022-12-01)

Efavirenz challenge in patients with nevirapine induced Stevens-Johnson Syndrome
by: Thandekile C. Manzini, et al.
Published: (2016-12-01)

Pharmacogenetics of <i>CYP2A6</i>, <i>CYP2B6</i>, and <i>UGT2B7</i> in the Context of HIV Treatments in African Populations
by: Graeme R. Ford, et al.
Published: (2022-12-01)

CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01)

Development and validation of a HPLC analytical assay method for efavirenz tablets: a medicine for HIV infections
by: Osnir de Sá Viana, et al.
Published: (2011-03-01)

Perspectives of pharmacogenetics approach to personalized tamoxifen therapy
by: M I Savelyeva, et al.
Published: (2017-06-01)

Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe
by: Sandra Shawarira-Bote, et al.
Published: (2019-08-01)

Pharmacogenetics in Psychiatry: An Update on Clinical Usability
by: Ron H. N. van Schaik, et al.
Published: (2020-09-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Increased Acetylcholine Levels and Other Brain Effects in 5XFAD Mice after Treatment with 8,14-Dihydroxy Metabolite of Efavirenz
by: Natalia Mast, et al.
Published: (2022-07-01)

CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer’s disease
by: Alan J. Lerner, et al.
Published: (2022-12-01)

Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
by: Yenny
Published: (2009-12-01)

Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
by: Yenny Yenny
Published: (2016-02-01)

Pharmacogenetics of Lethal Opioid Overdose: Review of Current Evidence and Preliminary Results from a Pilot Study
by: Leen Magarbeh, et al.
Published: (2023-05-01)

MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?
by: Rafael eDe La Torre, et al.
Published: (2012-11-01)

Pharmacokinetics of Efavirenz 600mg in Combination with Rifampicin in Chinese HIV/TB Co-Infection Patients
by: Wang T, et al.
Published: (2023-07-01)

Principles of pharmacogenetics and pharmacogenomics /
by: Altman, Russ B. 205766, et al.
Published: (2012)